Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
18F-JNJ-64326067 · 1 trial · 1 indication
The Effective Dose (ED) per organ will be calculated using Organ Level Internal Dose Assessment (OLINDA) software. After injection of 370 megaBecquerel (MBq) of 18F-JNJ-64326067, a series of whole-body positron emission tomography (PET) images will be obtained over a period of up to 6 hours and corrected for attenuation by computed tomography (CT) transmission scans using PET/CT. The unit of radioactivity will be milli Sieverts per mega Becquerel (mSv/MBq) for each organ and the effective dose per participant. The final values will be averaged across the participants.
The ED for whole body will be calculated using OLINDA software. After injection of 370 MBq of 18F-JNJ-64326067, a series of whole-body PET images will be obtained over a period of up to 6 hours and corrected for attenuation by CT transmission scans using PET/CT. The unit of radioactivity will be mSv/MBq for the whole body and the effective dose per participant. The final values will be averaged across the participants.
| Arm | Type | Description |
|---|---|---|
| 18F-JNJ-64326067 | EXPERIMENTAL | Participants will receive single intravenous (IV) bolus injection of 18F-JNJ-64326067 on Day 1. |
| Name | Type | Description |
|---|---|---|
| 18F-JNJ-64326067 | DRUG | 18F-JNJ-64326067 will be administered intravenously between a dose of 185 Megabecquerel (MBq) to 370 MBq. |
Inclusion Criteria: * Otherwise healthy for their age group on the basis of physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG) performed at screening or Day 1 predose. If there are abnormalities, they must be consistent with the age of the study population. This...
18F-JNJ-64326067 is an investigational small molecule positron emission tomography (PET) imaging ligand developed by Johnson & Johnson. It is labeled with fluoride-18, a radioactive isotope used in PET scanning, and was studied in healthy participants to evaluate its whole body distribution and radiation dosimetry.
18F-JNJ-64326067 is being developed by Johnson & Johnson, which trades on the New York Stock Exchange under the ticker JNJ. The company sponsored the Phase 1 study of the imaging agent.
18F-JNJ-64326067 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA. One Phase 1 trial has been completed, and no active trials are currently listed.
18F-JNJ-64326067 has been evaluated in one completed Phase 1 trial, NCT03581916, titled "A Study to Investigate the Whole Body Distribution and Radiation Dosimetry of the Positron Emission Tomography Ligand Fluoride-18 (18F)-JNJ-64326067 in Healthy Participants." The trial enrolled 6 healthy volunteers in the United States.
The Phase 1 trial NCT03581916 was an uncontrolled study with 6 healthy participants, both male and female, aged 18 years and older. It was not randomized and not double blinded. The study assessed whole body distribution and radiation dosimetry of the PET ligand and has been completed.